A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä
High CIP2A immunoreactivity is an independent prognostic indicator in early-stage tongue cancer
Tekijät: Böckelman C, Hagström J, Mäkinen LK, Keski-Säntti H, Häyry V, Lundin J, Atula T, Ristimäki A, Haglund C
Kustantaja: NATURE PUBLISHING GROUP
Julkaisuvuosi: 2011
Journal: British Journal of Cancer
Tietokannassa oleva lehden nimi: BRITISH JOURNAL OF CANCER
Lehden akronyymi: BRIT J CANCER
Vuosikerta: 104
Numero: 12
Aloitussivu: 1890
Lopetussivu: 1895
Sivujen määrä: 6
ISSN: 0007-0920
DOI: https://doi.org/10.1038/bjc.2011.167
Tiivistelmä
BACKGROUND: No reliable prognostic markers exist for squamous cell carcinoma of the tongue, and its prognosis can even in early stages be unpredictable and survival poor despite treatment. A potential marker is oncoprotein cancerous inhibitor of PP2A (CIP2A), which acts as a prognostic marker in gastric and non-small cell lung cancers.
METHODS: We collected specimens of 73 stage T1N0M0 and T2N0M0 oral squamous cell carcinomas of the tongue, as well as samples from normal oral mucosa, dysplastic lesions, and invasive carcinomas (n = 39). All samples were stained for CIP2A by immunohistochemistry. Survival curves were constructed according to the Kaplan-Meier method. The Cox proportional hazard model served for univariate and multivariate survival analysis.
RESULTS: High CIP2A immunoreactivity predicted poor survival in tongue cancer patients (P = 0.027, logrank test). In multivariate survival analysis, CIP2A was an independent prognostic factor (HR 2.02, 95% confidence interval 1.07-3.82, P = 0.030). Cytoplasmic CIP2A expression was higher in severe dysplasia than in mild dysplasia.
CONCLUSION: Our results suggest that high CIP2A expression characterises aggressive disease. Acting as a prognostic marker it might be of help when choosing patients for adjuvant treatment in tongue cancer patients. British Journal of Cancer (2011) 104, 1890-1895. doi:10.1038/bjc.2011.167 www.bjcancer.com Published online 24 May 2011 (C) 2011 Cancer Research UK
BACKGROUND: No reliable prognostic markers exist for squamous cell carcinoma of the tongue, and its prognosis can even in early stages be unpredictable and survival poor despite treatment. A potential marker is oncoprotein cancerous inhibitor of PP2A (CIP2A), which acts as a prognostic marker in gastric and non-small cell lung cancers.
METHODS: We collected specimens of 73 stage T1N0M0 and T2N0M0 oral squamous cell carcinomas of the tongue, as well as samples from normal oral mucosa, dysplastic lesions, and invasive carcinomas (n = 39). All samples were stained for CIP2A by immunohistochemistry. Survival curves were constructed according to the Kaplan-Meier method. The Cox proportional hazard model served for univariate and multivariate survival analysis.
RESULTS: High CIP2A immunoreactivity predicted poor survival in tongue cancer patients (P = 0.027, logrank test). In multivariate survival analysis, CIP2A was an independent prognostic factor (HR 2.02, 95% confidence interval 1.07-3.82, P = 0.030). Cytoplasmic CIP2A expression was higher in severe dysplasia than in mild dysplasia.
CONCLUSION: Our results suggest that high CIP2A expression characterises aggressive disease. Acting as a prognostic marker it might be of help when choosing patients for adjuvant treatment in tongue cancer patients. British Journal of Cancer (2011) 104, 1890-1895. doi:10.1038/bjc.2011.167 www.bjcancer.com Published online 24 May 2011 (C) 2011 Cancer Research UK
Turun yliopiston Tutkimustietojärjestelmän portaali